Sponsored Content by: Collegium Pharmaceutical
14 Min.
Share
Leading with Science Innovation Designed Around How People Live
Collegium Pharmaceutical advances formulation and delivery innovation designed around real-world patient needs, supporting evidence-based prescribing and leveraging technology to enhance the complete treatment journey.

Topics Discussed

Collegium develops treatments for CNS conditions like ADHD and supports responsible pain management strategies.
ADHD affects 15.5 million adults and 6.5 million children, impacting attention, impulse control, and daily routines.
Complex conditions influence families, caregivers, and communities, extending far beyond the individual patient's experience.
Chronic pain affects 60 million U.S. adults, with treatment requiring understanding of daily function and quality of life.

Meet the Experts

photo_executive_Vikram-Karnani@2x
Vikram Karnani
President & Chief Executive Officer, Collegium Pharmaceutical
photo_executive_Jane-Gonnerman@2x
Jane Gonnerman
Executive Vice President, Collegium Pharmaceutical

Healthier people. Stronger communities.

Collegium Pharmaceutical is a dynamic biopharmaceutical company focused on delivering innovative medicines for individuals living with complex central nervous system (CNS) and pain conditions. The company prioritizes formulation and delivery innovation that adapts to real-life needs, recognizing that complex conditions require flexible treatment approaches.

Understanding that patients don’t face these challenges alone, Collegium is committed to supporting the caregivers, families, and communities integral to every treatment journey, ensuring comprehensive care beyond medication.